Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern

Chia-En Lien^{1,2}, Tsun-Yung Kuo^{1,3}, Yi-Jiun Lin¹, Wei-Cheng Lian¹, Meei-Yun Lin¹, Luke Tzu-Chi Liu¹, Yu-Chi Chou⁴, Charles Chen^{1,5*}

¹ Medigen Vaccine Biologics Corporation, Taipei City, Taiwan

² Institute of Public Health, National Yang-Ming Chiao Tung University, Taiwan

³ Department of Biotechnology and Animal Science, National Ilan University, Yilan County, Taiwan

⁴ Biomedical Translation Research Center (BioTReC), Academia Sinica

⁵ Temple University, Philadelphia, PA 19122, USA

*Corresponding author: charles@medigenvac.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 Abstract

34 Vaccination is currently the best weapon to control the COVID-19 pandemic. However, an alarming
 35 number of novel variants termed Variants of Concern (VoC) were found to harbor mutations that diminished
 36 the neutralizing capacity of antibodies elicited by the vaccines. We have investigated the neutralizing titers of
 37 antibodies from sera of humans and rats immunized with the MVC-COV1901 vaccine against pseudoviruses
 38 coated with the wildtype, D614G, B.1.1.7, or B.1.351 spike proteins. Rats vaccinated with two doses of
 39 adjuvanted S-2P retained neutralization activities against the B.1.351 variant, albeit with a slight reduction
 40 compared to wildtype. Phase 1 vaccinated subjects showed more reduced neutralization abilities against the
 41 B.1.351 variant. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing
 42 responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a
 43 subunit protein COVID-19 vaccine. The appearance of vaccine escape variants is a growing concern facing
 44 many current COVID-19 vaccines and therapeutics. Strategies should be adopted against the ever-changing
 45 nature of these variants. The observations of this study grant us valuable insight into preemptive strikes
 46 against current and future variants.

47 Introduction

48 RNA viruses are fast-evolving and can accumulate mutations due to their error-prone polymerases;
 49 however, bearing the largest and most complex RNA virus genome, coronaviruses such as the SARS-CoV-2
 50 have proofreading polymerases that allow them to slowly mutate over time to adapt to hosts compared to other
 51 RNA viruses¹. Since the beginning of the COVID-19 pandemic, mutants have been detected periodically. A
 52 number of them, termed Variants of Concern (VoC), were found to carry mutations in the crucial receptor-
 53 binding domain (RBD) for antibody recognition and neutralization. The most representative of these VoCs, all
 54 bearing an N501Y mutation in the spike RBD, are B.1.1.1.7, B.1.351, and P1, which were first reported in the
 55 UK, South Africa, and Brazil respectively²⁻⁴. The implication is the lowered neutralization capabilities of
 56 monoclonal antibodies and antibodies induced by vaccines, and these mutations could potentially render the
 57 current therapeutics and vaccines ineffective⁵. Major therapeutic and vaccine manufacturers such as
 58 Regeneron, Moderna, Pfizer, and AstraZeneca had published reports of variants including B.1.351 and P1 that
 59 were highly resistant to neutralization⁶⁻⁸. Studies have attributed the resistance to antibody neutralization in
 60 B.1.351 and P1 variants to triple mutations K417N, E484K, and N501Y in the spike protein RBD. E484K
 61 mutation alone rendering the protein refractory to antibody binding via steric hindrance⁶. The industry has
 62 scrambled for strategies to combat these emerging variants, including redesigning the vaccine to elicit either
 63 variant-specific or more broadly neutralizing antibodies or administering the additional dose to boost the
 64 immune response to compensate for the reduction in neutralization⁹⁻¹¹.

65 Medigen's MVC-COV1901 is a SARS-CoV-2 vaccine consisting of recombinant prefusion stabilized
 66 spike protein S-2P with CpG 1018 and aluminum hydroxide (alum) adjuvants which have been shown to
 67 induce a very high level of antibody titers in preclinical studies¹². We sought to ask whether MVC-COV1901
 68 could still defend against these variants with its ability to induce a high level of immunogenicity. We found
 69 that antisera taken from the phase 1 vaccinated subjects showed neutralization against the wildtype, D614G,
 70 and B.1.1.7 pseudoviruses, while B.1.351 pseudoviruses could be neutralized but to a lesser extent. It was also
 71 found that a higher antigen dose elicited better neutralizing antibody response.

72

73 Results

74 MVC-COV1901-induced antibodies in rats effectively neutralized variants comparable to the wildtype.

75 We took rat sera from previous toxicology studies to assess antibodies' neutralization ability against
 76 emerging variants and subjected them to wildtype and B.1.351 pseudovirus neutralization assays. As shown in
 77 Figure 1, the antibodies were still effective against the B.1.351, although the titers were reduced by 1.49 to 4.6-
 78 fold in ID₅₀ and 1.4 to 3.05-fold in ID₉₀ relative to wildtype. The overall trend is that with the increase of the
 79 amount of antigen or adjuvant, the differences between the neutralization titer of wildtype and B.1.351 decrease
 80 (Figure 1B).

81 In all, we have shown that antibodies elicited by MVC-COV1901 in rats could effectively neutralize the
 82 various variants, in particular, the B.1.351 variant.

83 Human antisera vaccinated with MVC-COV1901 neutralized D614G and B.1.1.7 variants but is 84 diminished against the B.1.351 variant.

85 After confirming that the antibodies induced by MVC-COV1901 in rats could neutralize the VoCs, we
 86 tested human serum samples taken from our phase 1 clinical trial drawn at four weeks after the second
 87 immunization with low, mid, or high doses of MVC-COV1901 (S-2P adjuvanted with CpG and alum). Figure
 88 2 presents the data from pseudovirus neutralization assay of human sera with the panel of wildtype, D614G,
 89 B.1.1.7, and B.1.351 variants. Although the neutralization titers dropped in D614G and B.1.1.7 compared to the
 90 wildtype, the reductions were not statistically significant. However, when comparing B.1.351 with the wildtype,
 91 the titers decreased significantly with the median ID₅₀ of low, mid, and high dose dropping from 311, 342, and
 92 633 to 36, 53, and 94, respectively (Figure 2A), and ID₉₀ of low, mid, and high dose dropped from 80, 85, and
 93 140 to 23, 26, and 36, respectively (Figure 2C). A dose-dependent effect could be observed when plotting each
 94 dose group's neutralizing titers against the variants (Figure 3A). The neutralization titers against B.1.351 could
 95 be increased by using a higher dose of antigen. Comparing to the wildtype, B.1.351 resulted in a 10.8 to a 12.8-
 96 fold reduction in neutralizing titers for ID₅₀ and 4.2 to 5.3-fold reduction in neutralizing titers for ID₉₀ (Figure
 97 3B).

98

99 Discussion

100 In this study, we showed that in humans, two injections of a subunit vaccine consisting of the prefusion
 101 spike protein (S-2P) adjuvanted with CpG 1018 and aluminum hydroxide were effective in inducing potent
 102 neutralization activity against pseudovirus expressing wildtype, D614G and B.1.1.7 variant spike proteins,
 103 albeit to a lesser extent to the B.1.351 variant. Our study showed that the neutralization titers against B.1.351,
 104 compared to the wildtype, reduced by 4.2 to 5.3-fold in neutralizing titers for ID₉₀, comparable to results from
 105 studies using Moderna Pfizer's vaccinee sera as reported by Wang et al. and others^{6, 13-14}. The data is also
 106 consistent with these studies' findings, which show slight changes of neutralization titers against the
 107 pseudoviruses of D614G or B.1.1.7. We used the sera from participants of our dose-finding, first-in-human
 108 clinical trial to obtain neutralizing titers against the pseudoviruses constructed based on the VoCs. With a fixed
 109 dose of CpG 1018 and aluminum hydroxide, the data showed that the absolute neutralizing titers against B.1.351
 110 increase with the increase of S-2P antigen in the formulation.

111 The decreasing difference between the neutralizing titer for wildtype and B.1.351 as the neutralizing tier
 112 of wildtype rises is biologically plausible for the below reasons. First, antibody functions other than
 113 neutralization have been shown to correlate with protection. The higher the overall neutralizing titer, the larger
 114 the reserve of other antibody functions that could be effective against the virus¹⁵⁻¹⁶. Second, the neutralizing
 115 antibodies elicited by MVC-COV1901's spike protein trimers are polyclonal, as multiple antigenic epitopes
 116 could be identified on the protein. The monoclonal antibody (mAb) activities abolished by the mutated site
 117 could theoretically be compensated when titers of other neutralizing monoclonal antibodies increase. Amanat
 118 et al.¹⁷ profiled the polyclonal antibodies induced by a SARS-CoV-2 spike mRNA vaccine. They demonstrated
 119 the co-dominance of mAbs targeting the N-terminal domain (NTD) and receptor-binding domain (RBD). The
 120 mAbs targeting RBD showed smaller abolishment of neutralizing activities against viral variants carrying
 121 E484K compared to that of NTD. The competing mAbs bind differentially to variants, suggesting the protective
 122 importance of the otherwise-redundant mAbs against the VoCs¹⁸. It is unclear if the proportion of neutralizing
 123 mAbs targeting NTD and RBD would change as the dose escalation was conducted in our first-in-human study,
 124 but the overall higher neutralizing antibody titer among the high dose antigen group means a higher dose of

effective mAbs against the viral variant in question (Fig. 1 and 2). Our findings suggest that the neutralizing antibody titers elicited by the wildtype strain correlate with the reaction against VoCs. The study results by Garcia-Beltran et al. using sera of 99 vaccinees of Pfizer and Moderna COVID-19 vaccines demonstrated that after the second dose of both vaccines, the neutralizing antibody titers against the pseudoviruses of VoCs increase significantly⁵. The above findings lead to our thinking that it might be a viable option to combat the VoCs by increasing the prototype antigen, the adjuvant, or the number of shots, without redesigning the antigen. Our study generates points of interest warranting further investigation: The possibility of epitope spreading by adjuvant CpG 1018 to extend antibody coverage; the potential of current SARS-CoV-2 vaccine design to protect against the infection of VoCs if the overall neutralizing titer is boosted by the increase of antigen, adjuvant, or the number of shots.

Developing a new COVID-19 vaccine to cope with the VoC is inherently reactive due to the following unknowns, the clinical significance of the emerging strain, the geographical distribution where the strain will be predominant, and how they will mutate further. The FDA has published guidance for the industry to change the antigen based on the VoC to gain regulatory approval using the data accrued from the earlier development stages¹⁹. Nevertheless, the rollout of variant-specific vaccine that targets a geographical area where the strain is dominant can compromise a vaccination program's feasibility and timeliness, particularly in a low-and-middle-income setting. Further, it is unknown if the phenomenon of "original antigenic sin" would cause a problem for COVID-19, as a redesigned antigen might preferentially boost the antibodies elicited by the original antigen²⁰. Thus, it is desirable to have a COVID-19 vaccine that can cover the emerging variants for a given period before the accumulated mutations lead to a clinically significant abolishment of the neutralizing capacity generated by the vaccine.

Among the emerging VoCs, the B.1.351 variant first reported in the Eastern Cape of South Africa is more problematic. In vitro study has demonstrated immune escapes of the variant from convalescent plasma collected from individuals infected by earlier variants. An attenuation of neutralization titers up to 200 folds with IC₅₀ was reported²¹. The implication of these findings at the individual level is possible reinfection by the variant after a previous episode of SARS-CoV-2 infection²². It raises the question of whether COVID-19 vaccines that

were designed based on the original virus could yield protection against the variant at the public health level. This study investigates how the MVC-COV1901 performs in vitro against the VoCs to evaluate if the MVC-COV1901 can yield clinical protection and inform further development strategy. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a subunit protein COVID-19 vaccine.

Our study's limitation is that the sera were taken four weeks after the second shot of MVC-COV19 when the immunity has peaked and starting to wane. Therefore, we could not evaluate the impact of waning immunity on the neutralizing capacity against the variants. The study cannot evaluate the role of T-cell responses elicited by the vaccine as it was reported that the T-cell responses to immunization may confer heterotypic coverage and is less affected by variants of concern²³. COVID-19 vaccines that conduct phase III clinical trials in South Africa when the B.1.351 strain became predominant showed considerably high protection against severe clinical endpoints, while overall efficacy is lower than sites outside of South Africa²⁴. Since there are no correlates of protection being published for either earlier strains or the emerging variants, it warrants further study on how the reduced neutralizing titers will translate to clinical endpoints.

Methods

Animal studies

Crl:CD Sprague Dawley (SD) rats were obtained from BioLASCO Taiwan Co. Ltd., and studies were conducted in the Testing Facility for Biological Safety, TFBS Bioscience Inc., and the Center of Toxicology and Preclinical Sciences, QPS Taiwan and immunized as previously described¹². Briefly, rats were immunized twice at two weeks apart with adjuvanted S-2P with dosing as indicated in Figure 1. The sera were harvested two weeks after the second injection and subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 Wuhan wildtype or B.1.351 variant spike proteins.

All procedures in this study involving animals were conducted to avoid or minimize discomfort, distress, or pain to the animals and were carried out in compliance with the ARRIVE guidelines (<https://arriveguidelines.org/>). All animal work in the current study was reviewed and approved by the

Institutional Animal Care and Use Committee (IACUC) with animal study protocol approval number TFBS2020-010 and CTPS-19-019-01.

Clinical trial

Forty-five subjects from the age of 20 to 49 were enrolled in a prospective, open-labeled, single-center dose-escalation phase 1 study with three separate sub-phases for participants from 20 to less 50 years of age. Each sub-phase consisted of 15 participants. The three different dose levels employed in this clinical trial are low dose (LD), mid-dose (MD) and high dose (HD) μ g of S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide for phase 1a, 1b, and 1c, respectively. The vaccination schedule consisted of two doses, administered by intramuscular (IM) injection of 0.5 mL in the deltoid region of the non-dominant arm, preferably 28 days apart, on Day 1 and Day 29. On Day 57 (4 weeks after the second administration), serum samples were taken for pseudovirus neutralization assays. This phase 1 trial has been registered on clinicaltrials.gov as NCT04487210.

Pseudovirus neutralization assay

Lentivirus expressing the SARS-CoV-2 spike proteins of the Wuhan-Hu-1 wildtype strain was constructed, and the neutralization assay performed as previously described¹². Lentiviruses expressing D614G, B.1.1.7, and B.1.351 variant spike proteins were constructed in the same manner but with the spike protein sequence replaced with the respective variant strain.

Statistical analysis

The analysis package in Prism 6.01 (GraphPad) was used for statistical analysis. Two-way ANOVA with Tukey's multiple comparison test and Kruskal-Wallis with corrected Dunn's multiple comparisons test were used to calculate significance as noted in respective figure descriptions. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$

202 Acknowledgments

203 We are grateful for the QPS Taiwan and TFBS Biosciences for toxicology studies involving rats. We thank
204 Hao-Yuan Cheng, I-Chen Tai, and Erh-Fang Hsieh of the clinical team for planning and execution of the phase
205 1 clinical trial.

207 Competing Interests

208 The authors declare no competing interests.

210 Data Availability

211 The datasets generated during and analyzed during the current study are available from the
212 corresponding author on reasonable request.

214 References

- 215 1. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS Coronaviruses: an RNA proofreading
216 machine regulates replication fidelity and diversity. RNA Biol. 8(2):270-9 (2011).
- 217 2. Rambaut A et al., Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK
218 defined by a novel set of spike mutations. Virological.org. [https://virological.org/t/preliminary-genomic-](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
219 [characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
220 [mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563) (2020)
- 221 3. Naveca F et al. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil.
222 Virological.org [https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-](https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596)
223 [amazonas-brazil/596](https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596) (2021)
- 224 4. Tegally H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related
225 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv
226 2020.2012.2021.20248640 (2020)
- 227 5. Garcia-Beltran WF et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced

- humoral immunity. medRxiv 2021.02.14.21251704 (2021)
6. Wang P et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 2021.01.25.428137; Wu K et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants bioRxiv 2021.01.25.427948 (2021)
7. Xie X et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. bioRxiv 2021.01.27.427998 (2021)
8. Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa medRxiv 2021.02.10.21251247 (2021)
9. Gillespie C. "Pfizer and Moderna Are Studying Possible COVID 'Booster' Shots—Why a Third Dose May Be Needed" Feb 25, 2021. Health.com <https://www.health.com/condition/infectious-diseases/coronavirus/pfizer-is-coming-out-with-a-booster-shot-for-their-covid-vaccine-what-is-this-and-why-is-it-needed> (2021)
10. Liu A. "AstraZeneca, Oxford race to update COVID-19 vaccine as study flags weak action against variant" Feb 8, 2021, Fierce Pharma <https://www.fiercepharma.com/pharma/astrazeneca-oxford-race-to-update-covid-19-vaccine-as-study-flags-weak-action-against> (2021)
11. Al Idrus A. "UK government taps CureVac to target COVID-19 variants with new vaccines" Feb 5, 2021, Fierce Biotech <https://www.fiercebiotech.com/biotech/u-k-government-taps-curevac-to-target-covid-19-variants-new-vaccines>
12. Kuo TY et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep 10, 20085 (2020)
13. Liu Y et al. Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. N Engl J Med. 2021 Feb 17. doi:10.1056/NEJMc2102017 (2021)
14. Wu K et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. N Engl J Med. 2021 Mar 17. doi:10.1056/NEJMc2102179 (2021)
15. Bartsch YC et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications 12(1): 1-8. (2021)

254 16. Schafer A et al. Antibody potency, effector function, and combinations in protection and therapy for
255 SARS-CoV-2 infection in vivo. *J Exp Med*. 218:e20201993 (2021)

256 17. Amanat F et al. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-
257 neutralizing antibodies that target both the NTD and the RBD. *medRxiv* 2021.03.07.21253098 (2021)

258 18. Tong P et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. *bioRxiv*
259 2021.03.10.434840 (2021)

260 19. Center for Biologics Evaluation and Research, US Food and Drug Administration. Emergency Use
261 Authorization for Vaccines to Prevent COVID-19: Appendix 2: Evaluation of Vaccines to Address
262 Emerging SARS-CoV-2 Variants. Issued Feb 22, 2021. <https://www.fda.gov/media/142749/download>

263 20. Moore JP and Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. *JAMA* 325(9):
264 821-822. (2021)

265 21. Cele S et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma.
266 *medRxiv* 2021.01.26.21250224 (2021)

267 22. Zucman et al. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. *Clin*
268 *Infect Dis*. 2021, ciab129 (2021)

269 23. Skelly DT et al. Vaccine-induced immunity provides more robust heterotypic immunity than natural
270 infection to emerging SARS-CoV-2 variants of concern. *Research Square* 2021 Feb 09
271 doi: 10.21203/rs.3.rs-226857/v1 (2021)

272 24. Herper M and Branswell H. “FDA scientists endorse J&J’s Covid vaccine, as new data shed light on
273 efficacy” Feb 24 2021, STAT News. <https://www.statnews.com/2021/02/24/new-data-shed-light-on->
274 [efficacy-of-jjs-single-dose-vaccine-against-covid-19/](https://www.statnews.com/2021/02/24/new-data-shed-light-on-)
275
276
277
278 \

Figures

Figure 1. Neutralization of SARS-CoV-2 pseudovirus bearing wildtype or B.1.351 variant spike proteins by antisera of rats vaccinated with adjuvanted S-2P. Rats were immunized twice at 2 weeks apart with the indicated amount of adjuvanted S-2P. For the 50 µg S-2P+750 µg CpG 1018 + 375 µg alum group, 3 males were pooled into one sample and 3 females were pooled into one sample. For the other three groups, 5 males were pooled into one sample and 5 females were pooled into one sample. These resulted in two pooled samples (N=2) for each dose group. (A) The antisera were harvested two weeks after the second injection, pooled as indicated above and subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 Wuhan wildtype or B.1.351 variant spike protein to determine the ID₅₀ and ID₉₀ titers of neutralization antibodies. (B) Fold reductions in neutralization titers (ID₅₀ and ID₉₀) were calculated by dividing wildtype neutralization titers by B.1.351 neutralization titers. Results are presented in (A) as geometric mean titers with error bars representing 95% confidence interval and (B) as mean values shown on top of the corresponding bar and error bars representing standard deviation.

Figure 2. Neutralization of SAR-CoV-2 pseudoviruses with wildtype or variant spike proteins by antisera of clinical trial subjects vaccinated with different doses of MVC-COV1901. Serum samples from clinical phase 1 trial of MVC-COV1901 subjects were collected 4 weeks after the 2nd immunization (56 days from the 1st immunization). (A and B) ID₅₀ and (C and D) ID₉₀ neutralizing titers for low dose (LD), mid-dose (MD), high dose (HD), and all dose groups were measured with pseudovirus neutralization assays. (A and C) Box plots with median represented by the bar and the box forming the 25% to 75% percentile and whiskers extend to min and max values. (B and D): Results are represented here with each dot representing individual serum sample neutralization titer and lines connect each sample from the WT, D614G, B.1.1.7, and B.1.351 neutralization titers. Kruskal-Wallis, with corrected Dunn's multiple comparisons test, was used to calculate significance. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$.

A

B

Figure 3. Neutralization of variant pseudoviruses across different doses and fold reduction in the neutralization of D614G, B.1.1.7, and B.1.351 variants relative to the wildtype. (A) ID₅₀ and ID₉₀ neutralizing titers of each dose group were plotted for the wildtype and variants. The bars and error bars represent geometric mean titers and 95% confidence interval, respectively. (B) Fold reduction in neutralization versus the wildtype was calculated by dividing ID₅₀ and ID₉₀ neutralization titers of wildtype by that of each variant. Results are plotted as bars and error bars indicating mean and standard deviation, respectively. Two-way ANOVA with Tukey's multiple comparison test was used to calculate significance. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.